HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles | Modern Pathology
About HER2-low mBC | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
New treatment options for metastatic HER2-low breast cancer | SpringerLink
Targeted immunotherapy for HER2-low breast cancer with 17p loss | Science Translational Medicine
Advances in HER2-positive and HER2-low Breast Cancer - YouTube
About HER2-low mBC | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Distinguishing HER2-Negative From HER2-Low Breast Cancer - Cancer Therapy Advisor
Aleix Prat #PrecisionOncology on Twitter: "Lession#7: HER2-low was not associated with overall survival in advanced HR-positive disease and TNBC link: https://t.co/c5KhTemecP https://t.co/nDwIlskQnU" / Twitter
Evolution of low HER2 expression between early and advanced-stage breast cancer - ScienceDirect
Evolution of HER2-low expression from primary to recurrent breast cancer | npj Breast Cancer
Enhertu approved in EU for HER2-low breast cancer
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEJM
Frontiers | HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
Cancers | Free Full-Text | Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry | Breast Cancer Research | Full Text
The Science of HER2-low Breast Cancer and Implications for the Pathology Team - YouTube
HER2-Low-Positive and HER2-Zero Tumors: Distinct Biological Subtypes? - HER2 -Low Breast Cancer
Cancers | Free Full-Text | Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
Selecting patients with HER2-low breast cancer: Getting out of the tangle - ScienceDirect
Report Back from SABCS 2021: What's the Latest in MBC Research? — Our MBC Life
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer - NCI
Frontiers | HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
![PDF] Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ddee8e193c6c1e41afcb14c0252f0baa4a0b57b4/2-Figure1-1.png "PDF] Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. | Semantic Scholar")
PDF] Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. | Semantic Scholar
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials - The Lancet Oncology
Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status | BMC Medicine | Full Text
